APM
CGON icon

Avidity Partners Management’s CG Oncology CGON Stock Holding History

Avidity Partners Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.4M Buy
1,398,948
+110,000
+9% +$7.19M 15.92% 2
2026
Q1 		$87.2M Sell
1,288,948
-183,751
-12% -$10.4M 17.67% 2
2025
Q4 		$61.1M Sell
1,472,699
-128,200
-8% -$5.31M 17.64% 2
2025
Q3 		$64.5M Buy
1,600,899
+100,957
+7% +$2.94M 14.68% 2
2025
Q2 		$39M Buy
1,499,942
+519,000
+53% +$12.5M 7.77% 1
2025
Q1 		$24M Sell
980,942
-116,858
-11% -$3.29M 4.58% 4
2024
Q4 		$31.5M Sell
1,097,800
-558,200
-34% -$19.1M 3.09% 7
2024
Q3 		$62.5M Buy
1,656,000
+359,775
+28% +$12.6M 3.19% 5
2024
Q2 		$40.9M Sell
1,296,225
-158,540
-11% -$5.5M 1.74% 20
2024
Q1 		$63.9M Buy
+1,454,765
New +$59.4M 2.06% 15

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avidity Partners Management's CGON Position: Q2 2026 in Review

Avidity Partners Management increased its CG Oncology (CGON) stake by 8.5% in Q2 2026, buying an estimated $7.19M and bringing the position to 1,398,948 shares worth $99.4M. The position accounts for 15.92% of the portfolio, ranked #2.

Avidity Partners Management first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Avidity Partners Management held 1,398,948 shares of CG Oncology worth $99.4M as of Q2 2026.
  • Avidity Partners Management bought 110,000 CG Oncology shares in Q2 2026, an estimated $7.19M.
  • CG Oncology made up 15.92% of Avidity Partners Management's portfolio in Q2 2026, its #2 holding.
  • Avidity Partners Management first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.